ARDX Logo

Ardelyx, Inc. (ARDX) 

NASDAQ$5.42
Market Cap
$1.29B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
83 of 925
Rank in Industry
61 of 528

ARDX Insider Trading Activity

ARDX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$3,374,58846
Sells
$11,916,9656194

Related Transactions

MOTT DAVID Mdirector4$3.37M0$0$3.37M
Rodriguez SusanChief Commercial Officer0$01$52,357$-52,357
Renz Justin AChief Financial Officer0$04$125,650$-125,650
Blanks RobertSee Remarks0$04$317,022$-317,022
Rosenbaum David P.Chief Development Officer0$011$1.37M$-1.37M
Williams Laura AChief Medical Officer0$06$1.51M$-1.51M
Felsch Robert OraSee Remarks0$03$1.88M$-1.88M
RAAB MICHAELPresident & CEO0$025$2.92M$-2.92M
GRAMMER ELIZABETH ASee Remarks0$07$3.75M$-3.75M

About Ardelyx, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing â€¦

Insider Activity of Ardelyx, Inc.

Over the last 12 months, insiders at Ardelyx, Inc. have bought $3.37M and sold $11.92M worth of Ardelyx, Inc. stock.

On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $2.13M and sold $5.47M worth of stock each year.

Highest buying activity among insiders over the last 12 months: MOTT DAVID M (director) — $3.37M.

The last purchase of 77,729 shares for transaction amount of $388,738 was made by MOTT DAVID M (director) on 2025‑02‑24.

List of Insider Buy and Sell Transactions, Ardelyx, Inc.

2025-03-07SaleRAAB MICHAELPresident & CEO
41,668
0.0176%
$5.36$223,199+2.45%
2025-02-24PurchaseMOTT DAVID Mdirector
77,729
0.0322%
$5.00$388,738+3.70%
2025-02-20SaleRAAB MICHAELPresident & CEO
22,964
0.0086%
$5.62$129,124-6.36%
2025-02-20SaleWilliams Laura AChief Medical Officer
4,941
0.0018%
$5.62$27,783-6.36%
2025-02-20SaleRenz Justin AChief Financial Officer
5,171
0.0019%
$5.62$29,077-6.36%
2025-02-20SaleGRAMMER ELIZABETH ASee Remarks
4,291
0.0016%
$5.62$24,128-6.36%
2025-01-31SaleRAAB MICHAELPresident & CEO
41,666
0.0176%
$5.36$223,355+1.49%
2025-01-21PurchaseMOTT DAVID Mdirector
199,000
0.0854%
$4.99$992,672+10.95%
2025-01-07SaleRAAB MICHAELPresident & CEO
41,666
0.0174%
$5.31$221,309+0.37%
2024-12-19PurchaseMOTT DAVID Mdirector
213,300
0.0889%
$4.67$996,580+14.29%
2024-12-10SaleRAAB MICHAELPresident & CEO
25,000
0.0105%
$5.26$131,620+1.14%
2024-11-25SaleRAAB MICHAELPresident & CEO
25,000
0.0107%
$5.38$134,483+2.00%
2024-11-20SaleRAAB MICHAELPresident & CEO
31,980
0.0132%
$4.79$153,328+8.74%
2024-11-20SaleBlanks RobertSee Remarks
4,941
0.002%
$4.79$23,690+8.74%
2024-11-20SaleWilliams Laura AChief Medical Officer
7,366
0.003%
$4.79$35,316+8.74%
2024-11-20SaleRenz Justin AChief Financial Officer
5,260
0.0022%
$4.79$25,219+8.74%
2024-11-20SaleGRAMMER ELIZABETH ASee Remarks
7,046
0.0029%
$4.79$33,782+8.74%
2024-11-20SaleRosenbaum David P.Chief Development Officer
7,184
0.003%
$4.79$34,444+8.74%
2024-11-13PurchaseMOTT DAVID Mdirector
215,868
0.0924%
$4.62$996,598+18.22%
2024-11-11SaleRAAB MICHAELPresident & CEO
2,743
0.0012%
$4.90$13,441+8.69%
Total: 354
*Gray background shows transactions not older than one year

Insider Historical Profitability

37.37%
MOTT DAVID Mdirector
2015494
0.8456%
$10.92M120+19.65%
RAAB MICHAELPresident & CEO
1635138
0.686%
$8.86M156+248.1%
Williams Laura AChief Medical Officer
303804
0.1275%
$1.65M115+248.1%
Renz Justin AChief Financial Officer
285968
0.12%
$1.55M120+248.1%
GRAMMER ELIZABETH ASee Remarks
181043
0.076%
$981,253.06241+117.06%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$8,217,280
112
46.33%
$1.31B
$831,902,292
108
9.34%
$1.56B
$20,297,544
73
103.06%
$1.58B
$54,590,806
65
21.84%
$1.25B
Ardelyx, Inc.
(ARDX)
$1,101,324,300
58
37.37%
$1.29B

ARDX Institutional Investors: Active Positions

Increased Positions122+53.98%22M+15.34%
Decreased Positions98-43.36%13M-9.01%
New Positions47New8MNew
Sold Out Positions36Sold Out3MSold Out
Total Postitions250+10.62%151M+6.33%

ARDX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Janus Henderson Group Plc$130,719.0010.25%24.39M+3M+13.28%2024-12-31
Blackrock, Inc.$99,275.007.78%18.52M+694,542+3.9%2024-12-31
Vanguard Group Inc$76,984.006.04%14.36M+767,111+5.64%2024-12-31
State Street Corp$62,138.004.87%11.59M-548,936-4.52%2024-12-31
Macquarie Group Ltd$55,458.004.35%10.35M+1M+15.62%2024-12-31
Eventide Asset Management, Llc$30,020.002.35%5.6M-2M-24.45%2024-12-31
Geode Capital Management, Llc$29,532.002.32%5.51M+21,988+0.4%2024-12-31
Millennium Management Llc$15,884.001.25%2.96M-1M-26.13%2024-12-31
Citadel Advisors Llc$13,350.001.05%2.49M+281,685+12.75%2024-12-31
Morgan Stanley$12,980.001.02%2.42M-712,788-22.74%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
2.18SellsBuysStrong BuyBuyHoldSellStrong SellARDXHighAverageLowSeries 4